Oviedo

• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lun … Ended
  2023-505540-19-00 10 2023-04-24 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended
  2022-501246-30-00 6 2023-03-08 Insomnia Disorder
• Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2 … Ended
  2024-512590-27-00 9 2023-03-08 Non-resectable locally advanced or metastatic HER2-positive breast can
• A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended
  2024-515744-23-00 1 2023-02-15 Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R A
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance … Ended
  2024-514293-46-00 4 2022-07-07 Unresectable locally advanced or metastatic urothelial cancer
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d … Ended
  2024-518403-22-00 6 2022-06-20 Diabetes mellitus II
• Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended
  2024-519691-10-00 6 2022-05-27 Septic Shock
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemo … Ended
  2023-503756-27-00 4 2022-03-31 Non-Small Cell Lung Cancer (NSCLC)
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 5 2022-03-28 Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
• Long-term Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder Ended
  2024-512108-20-00 5 2022-03-16 Obsessive Compulsive Disorder
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM … Ended
  2023-508213-16-00 4 2022-03-15 Multiple Myeloma
• Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progress … Ended
  2024-518875-73-00 5 2021-12-10 Huntington Disease
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended
  2022-500752-39-00 5 2021-11-25 Prevention of Respiratory syncytial virus (RSV) infection in infants a
• A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended
  2024-512880-30-00 5 2021-08-27 Neovascular Age-related Macular Degeneration (wet AMD)
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma

Showing 265–288 of 309 trials